The immunosuppressive activity of artemisinin‐type drugs towards inflammatory and autoimmune diseases
T Efferth, F Oesch - Medicinal research reviews, 2021 - Wiley Online Library
The sesquiterpene lactone artemisinin from Artemisia annua L. is well established for
malaria therapy, but its bioactivity spectrum is much broader. In this review, we give a …
malaria therapy, but its bioactivity spectrum is much broader. In this review, we give a …
Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture
I Koneczny, R Herbst - Cells, 2019 - mdpi.com
Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction (NMJ).
Autoantibodies target key molecules at the NMJ, such as the nicotinic acetylcholine receptor …
Autoantibodies target key molecules at the NMJ, such as the nicotinic acetylcholine receptor …
Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology
ML Fichtner, R Jiang, A Bourke, RJ Nowak… - Frontiers in …, 2020 - frontiersin.org
Myasthenia gravis (MG) is a prototypical autoantibody mediated disease. The
autoantibodies in MG target structures within the neuromuscular junction (NMJ), thus …
autoantibodies in MG target structures within the neuromuscular junction (NMJ), thus …
Treatment considerations in myasthenia gravis for the pregnant patient
NE Gilhus - Expert Review of Neurotherapeutics, 2023 - Taylor & Francis
Introduction Myasthenia gravis (MG) is an autoimmune disease where muscle antibodies
form against the acetylcholine receptor (AChR), MuSK, or LRP4 at the neuromuscular …
form against the acetylcholine receptor (AChR), MuSK, or LRP4 at the neuromuscular …